About Pfenex
Pfenex is a Healthcare company based in San Diego (United States) founded in 2009, and was acquired by Ligand Pharmaceuticals in August 2020. Clinical-stage development of non-glycosylated biosimilar therapeutics. Pfenex has raised $24 million across 1 funding round from investors including Dow, Ligand Pharmaceuticals and Signet Healthcare Partners. The company has 80 employees. Pfenex offers products and services including Pfenex Expression Technology, Prima RNApols, and PeliCRM197. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its legal entity is Primrose Bio, Inc. Its competitors include Kriya Therapeutics, Annexon and Aldeyra; 3 of its 3 listed competitors have raised funding.
Company details
Pfenex is a clinical-stage biotechnology company focused on recombinant protein expression for applications including therapeutic proteins, vaccines, research, reagents and biosimilars. The companys lead product candidate (in partnership with Pfizer) is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. In addition, Pfenex has seven other biosimilars in various stages of development, including three with India-based Strides Acrolab, and two vaccines for anthrax and malaria.
- Headquarters San Diego, United States
- Employees 80
- Stage Acquired
- SectorsHealthcare
- Website pfenex.com
- Social LinkedIn X
- Acquired by Ligand Pharmaceuticals (Aug 2020)
- Legal Name Primrose Bio, Inc.
- Total Equity Funding$24M (USD)
in 1 rounds
- Latest Funding Round$24M (USD), Series A
Dec 2009
- InvestorsDow
& 2 more
- Employee Count80
- Acquired byLigand Pharmaceuticals
(Aug 2020)
Products & Services of Pfenex
Pfenex offers a comprehensive portfolio of products and services, including Pfenex Expression Technology, Prima RNApols, and PeliCRM197.
Platform for high-yield recombinant protein production using Pseudomonas fluorescens.
System for mRNA manufacturing and evaluation in therapeutic applications.
Carrier protein for vaccines and biologics production.
Funding Insights of Pfenex
Pfenex has successfully raised a total of $24M through 1 strategic funding round. The most recent funding activity was a Series A round of $24 million completed in December 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24M
- Total Rounds 1
- Last Round Series A — $24M
- First Round $24M
(Dec 2009)
- Investors Count 2
All 1 funding rounds of Pfenex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2009 | $24M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Pfenex
Pfenex has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Dow, Ligand Pharmaceuticals and Signet Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in North America and Europe | signethealthcarepartners.com | New York, United States | ||
Dow Inc. is engaged in materials science and chemical manufacturing. | 1897 | dow.com | Saginaw, United States | |
Pharmaceutical drugs are manufactured and developed in the United States. | 1987 | ligand.com | San Diego, United States |
Investor details for Pfenex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pfenex
2 people are tracked at Pfenex (2 in leadership); the tracked headcount is 80.
| Name | Role | Group |
|---|---|---|
Eef Schimmelpennink | Chief Executive Officer | Leadership |
Ryan Haverstock | Director, Business Development | Leadership |
Complete people profiles for Pfenex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pfenex
4 dated milestones of Pfenex across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Pfenex is founded.
- Funding First funding round of $24.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Ligand Pharmaceuticals.
Competitors of Pfenex
Pfenex has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Annexon and Aldeyra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. |
Detailed competitors of Pfenex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pfenex
Websites that share an audience with Pfenex (pfenex.com).
Websites whose visitors overlap most with Pfenex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| echotx.com | 100% | View details |
Top companies in Ophthalmology
3 companies that operate in the same segment as Pfenex (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pfenex
Complete news archive for Pfenex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pfenex
Pfenex was founded in 2009.
Pfenex is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Pfenex is a funded company, having raised a total of $24M across 1 funding round to date. The company's 1st funding round was a Series A of $24M, raised on Dec 2009.
Pfenex has 80 employees.
Pfenex is a clinical-stage biotechnology company focused on recombinant protein expression for applications including therapeutic proteins, vaccines, research, reagents and biosimilars. The companys lead product candidate (in partnership with Pfizer) is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. In addition, Pfenex has seven other biosimilars in various stages of development, including three with India-based Strides Acrolab, and two vaccines for anthrax and malaria.
Pfenex's top competitors include Annexon, Aldeyra and Kriya Therapeutics.
Pfenex offers Pfenex Expression Technology, Prima RNApols, and PeliCRM197.
Pfenex has 3 investors. Key investors include Dow, Ligand Pharmaceuticals, and Signet Healthcare Partners.
Pfenex operates through Primrose Bio, Inc..
Yes. Pfenex was acquired by Ligand Pharmaceuticals in August 2020.